Arcadia Medicine, a San Francisco-based biotech startup developing MDMA-like empathogens, this month closed roughly $9.25 million in seed financing and won FDA clearance to begin human testing of an “safer” alternative to MDMA. The post What Is Sam Altman’s Involvement in MDMA Developer Arcadia, and Why Does It Matter? appeared first on Psychedelic Health.
